Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective/background: Sickle cell disease (SCD) is a monogenic disease with a highly variable phenotype depending on the amount of fetal hemoglobin (HbF), the main modulator. Variation of HbF levels among patients is genetically regulated. HbF determines both the phenotype of the disease and the response to treatment with the main drug used, hydroxyurea. The efforts of the researchers have focused on discovering the genetic factors responsible for HbF variation, mainly describing the haplotypes of the β cluster and single nucleotide polymorphisms (SNPs) at three different loci: BCL11A, HBS1L-MYB, and the β-globin cluster. This study aimed to determine the possible correlation between the number of SNPs and haplotypes with higher HbF levels in a cohort of patients with SCD. A positive association could explain why certain haplotypes, such as Senegal or Arab-Indian, show higher HbF levels and less severe disease.
Methods: To test this hypothesis, the characterization of haplotypes was performed using the PCR-RFLP technique and genotyping of three SNPs representative of the three loci with the greatest association with HbF variation: I (rs7482144), BCL11A (rs4671393), and HBS1L-MYB (rs9376092).
Results: We found more SNPs in haplotypes related to higher HbF than those with less HbF, although only the SNP I (rs7482144) showed a statistically significant association.
Conclusion: We found a direct correlation between haplotypes and the number of SNPs. Haplotypes with higher levels of HbF and less severe phenotypes showed a higher number of SNPs. Thus, the Benin and Bantu haplotypes traditionally associated with poor prognosis showed the fewest mutated SNPs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11864215 | PMC |
| http://dx.doi.org/10.3389/fmed.2025.1347026 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
WGCNA and LASSO regression-based selection and validation of microRNA biomarkers of β-thalassemia.
Blood Cells Mol Dis
September 2025
NHC Key Laboratory of Thalassemia Medicine, The First Afliated Hospital of Guangxi Medical University, Nanning, Guangxi, China; Guangxi Key Laboratory of Thalassemia Research, Life Sciences Institute, Guangxi Medical University, Nanning, Guangxi, China. Electronic address:
Objective: In patients with severe β-thalassemia, fetal hemoglobin (HbF) upregulation may provide an avenue to better therapeutic outcomes. The mechanisms that regulate the expression of HbF, however, are currently unclear. This study was developed with the goal of exploring biomarkers and molecular mechanisms associated with HbF expression to help inform the development of novel therapeutic strategies.
View Article and Find Full Text PDFImpact upfront: novel format for Novo Nordisk Foundation funding.
Health Res Policy Syst
September 2025
Health Economics Research Group, Department of Health Sciences, Brunel University of London, London, United Kingdom.
Many retrospective assessments of the wider, societal impacts from health research funding use the Payback Framework or other frameworks. Much of this experience was collated in the 2018 Statement by the International School on Research Impact Assessment (ISRIA). Despite increased interest, especially in engaged research and a wider range of evaluation approaches, rarely do health and other research funders take a prospective approach and analyse the potential impact from a proposal to inform an impact management approach aimed at boosting impact.
View Article and Find Full Text PDFComparison of culture media supplements identifies serum components in self-reported serum-free preparations.
Stem Cell Res Ther
August 2025
Transfusion Research Center, Belgian Red Cross Flanders, Ottergemsesteenweg 413, Ghent, 9000, Belgium.
Background: Cell culture media are essential for cell expansion and many cells still depend on blood-derived supplements for optimal growth. From a regulatory perspective, these materials are ideally xeno-free, serum-free or even chemically defined. However, differences in composition and in performance are seldom clear from the terminology used in this field.
View Article and Find Full Text PDFA prime editing strategy to rewrite the γ-globin promoters and reactivate fetal hemoglobin for sickle cell disease.
Blood
August 2025
Université Paris Cité, Imagine Institute, Laboratory of chromatin and gene regulation during development, INSERM UMR1163, 75015, Paris, France, Paris, France.
Fetal hemoglobin (HbF) reactivation is a promising therapy for β-hemoglobinopathies. We developed a prime-editing strategy that introduces multiple mutations in the fetal γ-globin promoters that are expected to increase their activity. We tested multiple targets and optimized a variety of parameters to achieve ~50% of precise edits in a hematopoietic cell line, with minimal off-targets effects.
View Article and Find Full Text PDFImplementation of a fully automated ADAMTS13 activity assay utilizing fluorescence resonance energy transfer with a practical approach to address high background fluorescence interference.
Am J Clin Pathol
August 2025
Department of Pathology, Stanford University School of Medicine, Stanford, CA, United States.
Objective: This study evaluates an automated fluorescence resonant energy transfer (FRET)-based ADAMTS13 activity assay on the Ceveron S100 instrument for the diagnosis of thrombotic thrombocytopenic purpura. It addresses the challenge of high background fluorescence (HBF), a known concern from our manual FRET assay, and proposes strategies to minimize erroneous results.
Methods: We compared FRET-Ceveron results with FRET-Manual (n = 100) and Technozym (Technoclone) enzyme-linked immunosorbent assay (ELISA) (n = 52) using retrospective and prospective patient samples collected throughout 2024, alongside proficiency samples and standards with assigned values (n = 24).